WSJ Reports Late-Stage Venture Funds Defying Expected Decline

Late-stage venture funds have delivered strong recent performance, according to a Wall Street Journal report titled "Strong Performance in Late-Stage Venture Upends Common Wisdom." The claim cuts against the prevailing narrative that growth-stage investing has been the weakest link in private markets since the 2021–2022 valuation reset.

The Journal's headline alone marks a departure from routine coverage. For roughly two years, the consensus among limited partners and analysts has run the other way: late-stage funds, marked up most aggressively during the zero-rate era, were expected to post the deepest losses. If the Journal's reporting holds up, that consensus deserves a second look.

Notably, the headline says the results "upend common wisdom" — not that the sector has recovered outright. The distinction matters. Strong relative performance can mean late-stage funds fell less than expected, not that they generated the outsized returns of 2020 and 2021.

What is actually being claimed?

The source material available for this piece consists of the headline and publication attribution. The Wall Street Journal has not made the underlying figures available in the excerpt reviewed here. That means specific return numbers, fund vintages and manager names remain behind the Journal's paywall.

What can be stated with confidence is narrow:

• The Wall Street Journal reports strong performance in late-stage venture.
• The publication frames this result as contradicting widely held expectations.
• The report concerns venture funds investing at the growth stage, not seed or early-stage vehicles.

Readers should treat any broader interpretation — about specific funds, exits or distributions — as unverified until the full reporting is reviewed.

Why the surprise matters

Late-stage venture sat at the center of the private-market repricing that began in 2022. Growth funds had paid peak multiples for mature startups; when public comparables collapsed, those positions were the most exposed. Institutional investors responded by cutting growth allocations and steering capital toward earlier vintages and secondaries.

Against that backdrop, a report of strong late-stage returns raises a straightforward question: which funds, and measured how? Interim performance in private markets depends heavily on valuation methodology, and markdowns applied conservatively in 2022 may now be reversing as marks catch up with a firmer IPO and M&A environment. The Journal's framing suggests the market misjudged the damage.

It may equally suggest the damage was real but concentrated — spread unevenly across managers rather than across the entire stage.

What the report does not say

The headline makes no claim about distributions returning cash to investors, which remains the hardest test of any performance figure. Mark-to-model gains are not the same as realized returns. Until cash-on-cash numbers appear, the strength the Journal describes is a paper story with a promising arc.

The takeaway in plain words: a respected outlet now says late-stage venture performed better than almost anyone expected, but the numbers behind that claim — and whether cash actually returned to investors — remain to be seen. If the full report identifies the outperforming funds, expect limited partners to revisit growth-stage allocations in the next fundraising cycle.